Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease

被引:76
|
作者
Fitzmaurice, PS
Ang, L
Guttman, M
Rajput, AH
Furukawa, Y
Kish, SJ
机构
[1] Ctr Addict & Mental Hlth, Human Neurochem Pathol Sect, Human Neurochem Pathol Lab, Toronto, ON M5T 1R8, Canada
[2] Univ Western Ontario, Hlth Sci Ctr, Div Neuropathol, London, ON N6A 5C1, Canada
[3] Univ Saskatchewan, Div Neurol, Saskatoon, SK, Canada
[4] Ctr Addict & Mental Hlth, Movement Disorders Res Lab, Toronto, ON M5T 1R8, Canada
关键词
Parkinson's disease; progressive supranuclear palsy; multiple system atrophy; substantia nigra; glutathione; oxidative stress;
D O I
10.1002/mds.10486
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD. as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [-30%], PSP [-21%]), whereas a similar decrease in the MSA patient Group did not reach statistical significance (P = 0.078, MSA [-20%]). GSH levels were normal in all examined normal and degenerating extra-nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient Groups (-19 to -30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. (C) 2003 Movement Disorder Society.
引用
收藏
页码:969 / 976
页数:8
相关论文
共 50 条
  • [21] Pathogenesis of nigral cell death in Parkinson's disease
    Przedborski, S
    PARKINSONISM & RELATED DISORDERS, 2005, 11 : S3 - S7
  • [22] Role of Glutathione in Parkinson's Disease Pathophysiology and Therapeutic Potential of Polyphenols
    Niu, Chengu
    Dong, Miaoxian
    Niu, Yingcai
    PHYTOTHERAPY RESEARCH, 2024, 38 (12) : 5567 - 5582
  • [23] Structural MRI in Idiopathic Parkinson's Disease
    De Micco, Rosa
    Russo, Antonio
    Tessitore, Alessandro
    IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, 2018, 141 : 405 - 438
  • [24] On the Role of Iron in Idiopathic Parkinson's Disease
    Huenchuguala, Sandro
    Segura-Aguilar, Juan
    BIOMEDICINES, 2023, 11 (11)
  • [25] Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson's Disease and Multiple System Atrophy
    Visanji, Naomi P.
    Collingwood, Joanna F.
    Finnegan, Mary E.
    Tandon, Anurag
    House, Emily
    Hazrati, Lili-Naz
    JOURNAL OF PARKINSONS DISEASE, 2013, 3 (04) : 523 - 537
  • [26] Nigral iron deposition occurs across motor phenotypes of Parkinson's disease
    Jin, L.
    Wang, J.
    Jin, H.
    Fei, G.
    Zhang, Y.
    Chen, W.
    Zhao, L.
    Zhao, N.
    Sun, X.
    Zeng, M.
    Zhong, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (07) : 969 - 976
  • [27] Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease
    Naduthota, Rajini M.
    Honnedevasthana, Arush Arun
    Lenka, Abhishek
    Saini, Jitender
    Geethanath, Sairam
    Bharath, Rose Dawn
    Christopher, Rita
    Yadav, Ravi
    Gupta, Arun Kumar
    Pal, Pramod Kumar
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 382 : 61 - 65
  • [28] Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts
    Langley, Jason
    He, Naying
    Huddleston, Daniel E.
    Chen, Shengdi
    Yan, Fuhua
    Crosson, Bruce
    Factor, Stewart
    Hu, Xiaoping
    MOVEMENT DISORDERS, 2019, 34 (03) : 416 - 420
  • [29] Potential use of glutathione as a treatment for Parkinson's disease
    Wang, Hai-Li
    Zhang, Jun
    Li, Yu-Ping
    Dong, Lun
    Chen, Ying-Zhu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (02)
  • [30] Plasma Glutathione and Prodromal Parkinson's Disease Probability
    Charisis, Sokratis
    Ntanasi, Eva
    Stamelou, Maria
    Xiromerisiou, Georgia
    Maraki, Maria
    Veskoukis, Aristidis S.
    Yannakoulia, Mary
    Kosmidis, Mary H.
    Anastasiou, Costas A.
    Giagkou, Nikolaos
    Dardiotis, Efthimios
    Hadjigeorgiou, Georgios
    Sakka, Paraskevi
    Kouretas, Demetrios
    Stefanis, Leonidas
    Scarmeas, Nikolaos
    MOVEMENT DISORDERS, 2022, 37 (01) : 200 - 205